New York, NY – December 1, 2006 – The Spinal Muscular Atrophy Foundation announces the addition of Ivan Lieberburg, Ph.D., M.D. and Edward Kaye, M.D. to its Scientific Advisory Board. They join a distinguished group of business and scientific leaders who help formulate and execute the SMA Foundation’s drug discovery programs...

New York, NY – November 10, 2006 – The Spinal Muscular Atrophy (SMA) Foundation announced today that it has received the 2006 Advocacy Award of Merit from the Child Neurology Foundation (CNF). The award was...

The Woodlands, Texas - October 11, 2006 – Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that its research program to identify targets that may be important in the development of drugs to prevent...

New York, NY – June 7, 2006 – The Spinal Muscular Atrophy Foundation today announced that they have initiated a research and development collaboration with PTC Therapeutics, Inc. (PTC). The collaboration is designed to leverage PTC’s proprietary Gene Expression Modulation by...

WASHINGTON, D.C. -- Senators urged research advocacy groups and universities yesterday to step up efforts to win more federal funding for the National Institutes of Health, the federal agency that funds most of the country's medical research but is facing a third consecutive year of cuts.

Reprinted with permission from the American Academy of Neurology from Neurology Today; May 16, 2006, Volume 6(10):16-19.

The Woodlands, Texas - May 11, 2006 – Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it was awarded a grant from the United States Army Medical Research & Materiel Command (USAMRMC) for the identification of targets that may be important...

February 24, 2006 – PsychoGenics Inc. Tarrytown, New York and the Spinal Muscular Atrophy (SMA) Foundation have extended their research agreement to establish and behaviorally phenotype transgenic in vivo models of SMA and test potential therapeutics using these models.

New York, NY - January 31, 2006 - The Spinal Muscular Atrophy Foundation announced the completion of a new licensing agreement that will facilitate access to intellectual property fundamental to drug discovery efforts for the disease. Spinal muscular atrophy (SMA) is the leading genetic killer...